Shanghai in East China has been extending its administrative adjudications of pharm patent infringement disputes in recent years – in so doing, providing a solid guarantee for the city's biomedicines industry so that it can continue to expand.

In 2019, the Shanghai Intellectual Property Administration, or SIPA dealt with its first such dispute and it has since been paying special attention to the high-tech field of biomedicines and has convened nine adjudications of biomedical patent infringement disputes.

The claimants were all influential international pharmaceutical enterprises, including Takeda Pharmaceutical Company Limited and Bayer Healthcare Company Limited. All parties concerned in the cases accepted the adjudication results and none subsequently filed an administrative lawsuit.

SIPA is also understood to have been actively exploring a mechanism for early settlements of pharm patent disputes. It has carried out a raft of activities in the field of intellectual property rights protection – building trust in the sector, so that companies now tend to prefer to choose the administrative ruling procedure to solve their disagreements.